TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00528567
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab was administered at a dose equivalent of 5 mg/kg/week using 1 of 3 different scheduling options depending on the schedule of the adjuvant chemotherapy regimen selected for an individual patient.
Study: NCT00357565
Drug: busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered 1.1 mg/kg if \<12 kg intravenous (IV) every 6 hours (0.8 mg/kg if \>12 kg IV every 6 hours on Days -8 through -5.
Study: NCT00357565
Drug: cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive cyclosporine (CSA) therapy beginning on day -3 maintaining a level of \>200 ng/mL. For children \< 40 kg the initial dose will be 2.5 mg/kg intravenous (IV) over 2 hours every 8 hours.
Study: NCT00357565
Drug: fludarabine phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered 25 mg/m\^2 intravenous (IV) over 60 minutes on Days -4 through -2.
Study: NCT00357565
Drug: melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered 60 mg/m\^2 intravenous (IV) over 30 minutes on Days -4 through -2.
Study: NCT00357565
Drug: mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All patients will begin mycophenolate mofetil (MMF) on day -3. Patients \<45 kilograms will receive MMF at the dose of 15 mg/kg/dose every 8 hours (max dose 1gm/dose) orally or intravenously (PO or IV).
Study: NCT03085147
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: For PARRi-FL, imaging patients will first gargle a solution of PARRi-FL for 1 min, then spit out this solution and gargle with a cleaning solution (the solvent used for PARRi-FL) for 1 min. Then fluorescence imaging of the oral cavity and pharynx will be performed with an endoscope. The intensity and extent of the fluorescence signal will be recorded by one of the investigators for the tumor and adjacent normal mucosa.
Study: NCT02754765
Drug: Bedaquiline
Normalized name: Bedaquiline
DrugBank: Bedaquiline (DB08903)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02754765
Drug: Delamanid
Normalized name: delamanid
DrugBank: Delamanid (DB11637)
Approvals — FDA: no, EMA: yes, PMDA: yes
Study: NCT02754765
Drug: Clofazimine
Normalized name: Clofazimine
DrugBank: Clofazimine (DB00845)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02754765
Drug: Levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02754765
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02754765
Drug: Linezolid
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02754765
Drug: Pyrazinamide
Normalized name: Pyrazinamide
DrugBank: Pyrazinamide (DB00339)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01963793
Drug: Aprepitant
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprepitant gel (10 mg/g)
Study: NCT00916201
Drug: intranasal Insulin
Normalized name: INSULIN
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 160 IU / d for 5 days, intranasal
Study: NCT00911443
Drug: Dacarbazine + Interferon alpha
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dacarbazine 800 mg/m2 IV on day 1; Interferon alpha 3MIU SC on day 11 and 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
Study: NCT00916201
Drug: Cannabidiol CR
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 320 mg / d for 5 days, orally
Study: NCT00002779
Drug: fludarabine phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002779
Drug: octreotide acetate
Normalized name: Octreotide Acetate
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01372982
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole Tablets 2.5 mg of Dr.Reddy's Laboratories Limited
Study: NCT02521831
Drug: General Anesthesia (isoflurane)
Normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoflurane is a fluorinated ether with general anesthetic and muscle relaxant effects. Brand names include Forane and Terrell.
Study: NCT03074942
Drug: Reslizumab
Normalized name: Reslizumab
DrugBank: Reslizumab (DB06602)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Reslizumab 3 mg/kg once / every 4 weeks during 24 weeks
Study: NCT02048189
Drug: LEVEMIR
Normalized name: Levemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02048189
Drug: APIDRA
Normalized name: Apidra
DrugBank: Insulin glulisine (DB01309)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01998035
Drug: RomiDEPsin 10 MG/M2
DrugBank: Romidepsin (DB06176)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Romidepsin is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Romidepsin is classified as a Histone Deacetylase Inhibitor.~Dose escalation (10 mg/m2)
Study: NCT01998035
Drug: Oral 5-Azacitidine 100 MG
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A pyrimidine nucleoside analogue of cytidine with antineoplastic activity.~Dose escalation (100 mg)
Study: NCT01998035
Drug: Oral 5-Azacitidine 200 MG
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A pyrimidine nucleoside analogue of cytidine with antineoplastic activity.~Dose escalation (200 mg)
Study: NCT01998035
Drug: Oral 5-Azacitidine 300 MG
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A pyrimidine nucleoside analogue of cytidine with antineoplastic activity.~Dose escalation (300 mg)
Study: NCT04552223
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab 480mg administered intravenously on Day 1 of each 4 week cycle.
Study: NCT04552223
Drug: Relatlimab
Normalized name: Relatlimab
DrugBank: Relatlimab (DB14851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Relatlimab 160 mg administered intravenously on Day 1 of each 4 week cycle.
Study: NCT03515837
Drug: pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IV infusion
Study: NCT03515837
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV infusion
Study: NCT03515837
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV infusion
Study: NCT03515837
Drug: saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV infusion
Study: NCT04676412
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: oral capsule
Study: NCT04676412
Drug: Placebo for lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: oral capsule
Study: NCT00887107
Drug: Sorafenib (nexavar)
Normalized name: sorafenib Oral Tablet [Nexavar]
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 months therapy with Sorafenib 800 mg/day
Study: NCT01561586
Drug: Weekly cisplatin with RT
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 40mg/m2 IV Weekly For 6 Cycles.(The 6th cycle of cisplatin may be omitted if external beam radiation therapy has been completed) Cisplatin may be diluted and administered per established institutional guidelines. For general suggestion, 40 mg/ m2 of cisplatin may be diluted in 250 ml 0.9% sodium chloride and administered over one or two hours.~Cisplatin will be given on the first day of external RT (Day 1), preferably, and must be given prior to radiation treatment on that day~External beam RT will be followed by intracavitary brachytherapy. The total elapsed time for completion of external beam to the whole pelvis, intracavitary BT, and parametrial / nodal RT shall not exceed eight weeks (56 days)
Study: NCT01561586
Drug: Tri-weekly cisplatin with RT
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tri-weekly cisplatin 75mg/m2 three cycles concurrent to radiation therapy~Cisplatin may be diluted and administered per established institutional guidelines. For general suggestion, 75 mg/m2 of cisplatin may be diluted in 500 ml 0.9% sodium chloride and administered over one or two hours (rate of 1 mg of cisplatin per minute).~Cisplatin will be given on the first day of external RT (Day 1), preferably, and must be given prior to radiation treatment on that day.~External beam RT will be followed by intracavitary brachytherapy. The total elapsed time for completion of external beam to the whole pelvis, intracavitary BT, and parametrial / nodal RT shall not exceed eight weeks (56 days)
Study: NCT03006172
Drug: Inavolisib
Normalized name: Inavolisib
DrugBank: Inavolisib (DB15275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive oral inavolisib once daily on Days 1-28 of each 28-day cycle (Arms A, B, C, D, E, F) or Days 1-21 of each 21-day cycle (Arm G).
Study: NCT03006172
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive fulvestrant 500 mg, administered intramuscularly on Days 1 and 15 of Cycle 1. For subsequent cycles, participants will receive fulvestrant intramuscularly on Day 1 of each cycle.
Study: NCT03006172
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive once daily oral doses of letrozole 2.5 mg on Days 1-28 of each cycle.
Study: NCT03006172
Drug: Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive once daily oral doses of palbociclib 125 mg on Days 1-21 of each cycle.
Study: NCT03006172
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive oral metformin once daily, starting on Cycle 1, Day 1, as tolerated.
Study: NCT03006172
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive trastuzumab, administered by IV infusion on Day 1 of each 21-day cycle, at a loading dose of 8 mg/kg for Cycle 1 and a dose of 6 mg/kg for subsequent cycles, until disease progression or unacceptable toxicity.
Study: NCT03006172
Drug: Pertuzumab
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive pertuzumab, administered by IV infusion on Day 1 of each 21-day cycle, at a loading dose of 840 mg for Cycle 1 and a dose of 420 mg for subsequent cycles, until disease progression or unacceptable toxicity.
Study: NCT04645550
Drug: Apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: From postoperative day 3, patients will receive oral Apixaban 2.5mg bid for six months.
Study: NCT04645550
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: From postoperative day 3, patients will receive oral Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3 for six months.
Study: NCT04645550
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: From postoperative day 3, patients will receive oral Aspirin Enterie Ccoated Tablets 100mg qd for six months.
Study: NCT04645550
Drug: Dipyridamole
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months.
Study: NCT01133444
Drug: Finasteride
Normalized name: Finasteride
DrugBank: Finasteride (DB01216)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Finasteride tablets 1 mg
Study: NCT00111774
Drug: ABX-EGF
Normalized name: ABX-EGF
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00267020
Drug: enzastaurin
Normalized name: Enzastaurin
DrugBank: Enzastaurin (DB06486)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 milligrams (mg) loading dose then 500 mg, orally, daily, six 28-day cycles
Study: NCT00267020
Drug: gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 milligrams/square meter (mg/m\^2), intravenously on Days 1, 8 and 15 per cycle, six 28-day cycles
Study: NCT04682431
Drug: PY159 Single agent dose level 2
Normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose of PY159 as a single agent given in a standard 3+3 design.
Study: NCT04682431
Drug: PY159 Single agent dose level 3
Normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose of PY159 as a single agent given in a standard 3+3 design.
Study: NCT00506519
Drug: Antithrombin alfa (INN name)
DrugBank: Antithrombin Alfa (DB11166)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00506519
Drug: Control (Standard treatment)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04682431
Drug: PY159 Single agent dose level 4
Normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose of PY159 as a single agent given in a standard 3+3 design.
Study: NCT04682431
Drug: PY159 Single agent dose level 6
Normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose of PY159 as a single agent given in a standard 3+3 design.
Study: NCT04682431
Drug: PY159 Single agent dose level 7
Normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose of PY159 as a single agent given in a standard 3+3 design.
Study: NCT04682431
Drug: PY159/Pembrolizumab Combination dose level 1
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose of PY159 and given in combination with pembrolizumab
Study: NCT04682431
Drug: PY159/Pembrolizumab Combination dose level 2
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose of PY159 and given in combination with pembrolizumab
Study: NCT04682431
Drug: PY159/Pembrolizumab Combination dose level 3
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose of PY159 and given in combination with pembrolizumab
Study: NCT04682431
Drug: PY159/Pembrolizumab Combination dose level 4
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose of PY159 and given in combination with pembrolizumab
Study: NCT04682431
Drug: PY159/Pembrolizumab Combination dose expansion cohort 1
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
Study: NCT04682431
Drug: PY159/Pembrolizumab Combination dose expansion cohort 2
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
Study: NCT04682431
Drug: PY159/Pembrolizumab Combination dose expansion cohort 3
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
Study: NCT04682431
Drug: PY159/Pembrolizumab Combination dose expansion cohort 4
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
Study: NCT04682431
Drug: PY159/Pembrolizumab Combination dose expansion cohort 5
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
Study: NCT04682431
Drug: PY159/Pembrolizumab Combination dose expansion cohort 6
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose of PY159 as a single agent and in combination with pembrolizumab for predefined tumor histology
Study: NCT01665573
Drug: PF-04457845
Normalized name: PF-04457845
DrugBank: PF-04457845 (DB12012)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acquisition of conditioning Administration of drug Extinction of conditioning
Study: NCT00276731
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00276731
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00276731
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00276731
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04071366
Drug: Itacitinib
Normalized name: itacitinib
DrugBank: Itacitinib (DB12154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1: Itacitinib 200 mg once daily for 30 days. Part 2: Itacitinib 200 mg twice daily for 30 days.
Study: NCT04071366
Drug: Immune effector cell therapy
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive IEC therapy that is approved by the health authority in the country where the study is being conducted for any approved hematologic indication.
Study: NCT03150810
Drug: Pamiparib
Normalized name: Pamiparib
DrugBank: Pamiparib (DB14769)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by mouth as a capsule twice daily
Study: NCT03150810
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TMZ at various doses administered by mouth as a capsule once daily.
Study: NCT03206671
Drug: Rituximab window
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab window (375 mg/m²)
Study: NCT03206671
Drug: Additional doses of Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2 doses of Rituximab (375 mg/m²) before the start of the first chemotherapy cycle, 2 doses of Rituximab before the start of the second chemotherapy cycle, 1 dose of rituximab before the start of the third chemotherapy cycle, 1 dose of Rituximab before the start of the forth chemotherapy cycle
Study: NCT03206671
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: see detailed protocol description
Study: NCT03206671
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: see detailed protocol description
Study: NCT03206671
Drug: Vindesine Sulfate
Normalized name: vindesine sulfate
DrugBank: Vindesine (DB00309)
Approvals — FDA: no, EMA: no, PMDA: no
Description: see detailed protocol description
Study: NCT03206671
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: see detailed protocol description
Study: NCT03206671
Drug: Ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: see detailed protocol description
Study: NCT03206671
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: see detailed protocol description
Study: NCT02975882
Drug: Irinotecan Hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT02975882
Drug: Sirolimus Albumin-bound Nanoparticles
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT02975882
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT00669136
Drug: AFP + GM-CSF Plasmid Prime and AFP Adenoviral Vector Boost
Normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AFP + GM-CSF Plasmid Prime and AFP Adenoviral Vector Boost
Study: NCT04325984
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: To the Dexamethasone group, at the moment of the induction of anaesthesia, dexamethasone 8 mg is administered.
Study: NCT03844620
Drug: Regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given by mouth
Study: NCT02285140
Drug: Cefazolin
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: administration as outlined
Study: NCT02285140
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: administration as outlined
Study: NCT01973842
Drug: 0.1 mg triptorelin
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02503709
Drug: CDK Inhibitor AT7519
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02503709
Drug: Onalespib
Normalized name: Onalespib
DrugBank: Onalespib (DB06306)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT01973842
Drug: 0.2 mg triptorelin
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01973842
Drug: 0.4 mg triptorelin
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04409600
Drug: Botulinum Toxin Injection
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type B (DB00042)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: The participant will receive a botulinum toxin injection to their painful lower leg compartment(s).
Study: NCT03373409
Drug: Albuterol DPI 90mcg
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol unit dose disposable DPI delivers 90mcg of albuterol in the excipient lactose with each inhalation. Albuterol 90mcg will be given on one of the 3 treatment days. One inhalation from the DPI will be used.